RGNX has been in the news 450% more than usual
Mar 05, 2026, 11:32 PM
-2.35%
What does RGNX do
REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
RGNX has been in the news recently: REGENXBIO Inc. will present its gene therapy RGX-202 for Duchenne muscular dystrophy at the MDA Conference from March 8-11, 2026. Additionally, a class action lawsuit has been filed against REGENXBIO following a 17.8% drop in stock price due to a clinical hold on another gene therapy, RGX-111.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.